Loading clinical trials...
Loading clinical trials...
Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab
Conditions
Interventions
Lutetium Lu 177-PSMA-617
Pembrolizumab
Locations
1
United States
University of California, San Francisco
San Francisco, California, United States
Start Date
May 10, 2019
Primary Completion Date
January 10, 2024
Completion Date
January 10, 2024
Last Updated
February 25, 2025
NCT04693377
NCT06526299
NCT06705686
NCT04550494
NCT06305598
NCT04489719
Lead Sponsor
University of California, San Francisco
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions